Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

Itll take a few years for its latest moves to pay off, assuming they do.…

In our Newsletter published on 7TH December 2023, a section was included related to AstraZeneca BioVentureHub. This was not officially…

By John Vandermosten, CFA NASDAQ:ALLR Early Results - Phase II Stenoparib Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…

The Global Artificial Intelligence In Precision Medicine Market Size was valued at USD 1.28 Billion in 2022 and the Global…

AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, stands as a quintessential example of a growth at a reasonable price (GARP)…

JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and…

JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and…

…

The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock…

…

1 December 2023 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

AstraZeneca halts Phase III trials for kidney disease treatment…

The Pulse With Francine Lacqua is all about conversations with high profile guests in the beating heart of global business,…

1 December 2023 Update on CRYSTALIZE evidence trials Discontinuation of STABILIZE-CKD and DIALIZE-Outcomes Phase III trials AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes…

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III…

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Astrazeneca von 13000 auf 12500 Pence gesenkt, aber…

Barclays updates FTSE stock targets, AstraZeneca and Admiral rise…

…

Could AstraZeneca be an under-rated buy right now?…

Could AstraZeneca be an under-rated buy right now?…

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

…

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Evinova wird als eigenständiger Health-Tech-Geschäftsbereich innerhalb von…

J&Js (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on…

VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical…

Barclays Capital has issued an optimistic assessment of AstraZeneca PLC (LSE:AZN)s shares, recommending an "overweight" position with a target price…

AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with…

It might have a hard time finding a home in the market.…

The CDCs move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise…

17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer First-in-class AKT inhibitor has potential to reshape…

FDA approves AstraZenecas (AZN) new breast cancer drug, Truqap, and the expanded use of Mercks (MRK) Keytruda in a gastric…

AstraZenecas (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.…

…

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that,…

AstraZenecas (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.…

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in Studien mit Lungenkrebs-Patienten einen Rückschlag bei einem seiner Kassenschlager erlitten. Eine…

Im Wertpapierhandel ist der Anteilsschein von AstraZeneca zur Stunde unauffällig. Die Aktie notiert derzeit bei 63,37 US-Dollar. Der heutige Börsentag…

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

…

"The incumbent almost always wins," Jim Cramer said this week.…

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral…

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.…

AZN earnings call for the period ending September 30, 2023.…

…

…

AstraZeneca is the latest player to enter the weight loss drug market, which analysts predict could reach $100 billion by…

AstraZeneca CFO Aradhana Sarin discusses the companys third-quarter results and its plans to develop an obesity pill. The treatment developed…

The FTSE 100 gained on Thursday as macroeconomic concerns took a back seat and investors focused on corporate earnings. Upbeat…